Zoetis (NYSE:ZTS) Director Michael Mccallister Purchases 3,000 Shares

Zoetis Inc. (NYSE:ZTS) Director Michael Mccallister bought 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Zoetis Stock Performance

Shares of ZTS traded up $0.25 during midday trading on Tuesday, reaching $76.92. 18,424,772 shares of the stock were exchanged, compared to its average volume of 6,276,606. The business’s 50-day moving average price is $116.50 and its 200 day moving average price is $122.77. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a twelve month low of $75.11 and a twelve month high of $172.23. The company has a market capitalization of $32.25 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.25 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts expect that Zoetis Inc. will post 6.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ZTS shares. Bank of America boosted their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. BTIG Research restated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Stifel Nicolaus set a $105.00 price target on Zoetis in a research report on Friday. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $141.25.

Institutional Investors Weigh In On Zoetis

A number of institutional investors have recently added to or reduced their stakes in ZTS. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in shares of Zoetis during the 1st quarter worth approximately $28,000. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis during the 4th quarter worth approximately $30,000. Finally, Root Financial Partners LLC boosted its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.